Real-World Use of Fingolimod in Patients with Relapsing Remitting Multiple Sclerosis: A Retrospective Study Using the National Multiple Sclerosis Registry in Kuwait

被引：0
|
作者：
Jasem AL-Hashel
Samar F. Ahmed
Raed Behbehani
Raed Alroughani
机构：
[1] Ibn Sina Hospital,Department of Neurology
[2] Kuwait University,Faculty of Medicine
[3] Minia University,Department of Neurology and Psychiatry
[4] Al-Bahar Eye Center,Department of Ophthalmology
[5] Dasman Diabetes Institute,Neurology Clinic
[6] Amiri Hospital,Division of Neurology, Department of Medicine
来源：
CNS Drugs | 2014年 / 28卷
关键词：
Multiple Sclerosis; Expand Disability Status Scale; Natalizumab; Glatiramer Acetate; Fingolimod;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：817 / 824
页数：7
相关论文
共 50 条
  • [41] Safety and Effectiveness of Fingolimod in Real-World Multiple Sclerosis Portuguese Patients
    Ribeiro de Barros, Ariana Helena
    Fiadeiro Sequeira, Joao Paulo
    Lopes de Sousa, Ary Severino
    Chegancas Capela, Carlos Miguel
    Gomes Pedrosa, Rui Manuel
    dos Santos Manita, Manuel Alexandre
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (04) : 129 - 135
  • [42] Real-World Fingolimod efficacy and safety in Emirati patients with multiple sclerosis
    Ceccarelli, Antonia
    Mifsud, Victoria
    Elhennawy, Rawan Yasser Gaber
    Benedetti, Beatrice
    Hussain, Syed
    Samples, Stephen
    NEUROLOGY, 2019, 92 (15)
  • [43] Real-world safety and effectiveness of natalizumab treatment in patients with relapsing-remitting multiple sclerosis: data from an Irish registry
    McGuigan, C.
    Kinirons, P.
    Ryan, A.
    Moore, H.
    Murphy, S. M.
    Hennessy, M.
    Gibson, B.
    Hayden, B.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 299 - 300
  • [44] Effects of fingolimod in relapsing-remitting multiple sclerosis Comment
    Sorensen, Per Soelberg
    LANCET NEUROLOGY, 2014, 13 (06): : 526 - 527
  • [45] BUDGET IMPACT ANALYSIS OF FINGOLIMOD IN RELAPSING REMITTING MULTIPLE SCLEROSIS
    Ruggeri, M.
    D'Ausilio, A.
    Lo Muto, R.
    Cottone, S.
    Ghezzi, A.
    Mecozzi, A.
    Sacchini, D.
    Mangone, M.
    VALUE IN HEALTH, 2014, 17 (07) : A393 - A393
  • [46] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Vosiliou, S.
    DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
  • [47] Early use of fingolimod is associated with better clinical outcomes in relapsing–remitting multiple sclerosis patients
    Miryam Cannizzaro
    Laura Ferré
    Ferdinando Clarelli
    Antonino Giordano
    Francesca Sangalli
    Bruno Colombo
    Giancarlo Comi
    Lucia Moiola
    Vittorio Martinelli
    Massimo Filippi
    Federica Esposito
    Journal of Neurology, 2022, 269 : 5596 - 5605
  • [48] A retrospective analysis in patients with relapsing-remitting multiple sclerosis
    Maeurer, Mathias
    Lang, Michael
    Elias, Wolfgang
    Ries, Stefan
    Reifschneider, Stefan
    Kaefferlein, Wolfgang
    Windhagen, Susanne
    Wensdoerfer, Colin
    Niemczyk, Gabriele
    Schikhnaier, Petra
    Schwab, Stefan
    MULTIPLE SCLEROSIS, 2008, 14 : S164 - S165
  • [49] Real-world effectiveness of TYSABRI® (natalizumab) treatment in patients with relapsing remitting multiple sclerosis in Argentina and Chile
    Ysrraelit, C.
    Caride, A.
    Sinay, V.
    Rivera Kindel, M.
    Halfon, J.
    Patrucco, L.
    Piedrabuena, R.
    Diaz Aragunde, V.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 979 - 979
  • [50] Real-World Efficacy and Safety of Oral Cladribine in Korean Patients with Relapsing-Remitting Multiple Sclerosis
    Kim, Su-Hyun
    Kim, Ho Jin
    Kim, Sung Min
    Shin, Ha Young
    Kwon, Young Nam
    Nam, Tai-Seung
    Kim, Byoung Joon
    Min, Ju-Hong
    Kim, Jun Soon
    Su, Park Min
    Kim, Nam-Hee
    Shin, Jin-Hong
    Park, Young Eun
    Lim, Young-Min
    Lee, Eun-Jae
    Kim, Woojun
    Shon, Eun Hee
    Lee, Tae-Kyeong
    Taha, Karim
    Seo, Beom-Jun
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1099 - 1099
12345